

Technology Appraisal Committee D Interests Register

Topic: Rimegepant for treating or preventing migraine [ID1539]

Publication Date: 18/10/2023

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Professor David Meads	Committee member	Non-financial professional	University of Leeds has received funding from BMS, Sanofi and Janssen for research in an unrelated area.	20.12.2022 & 10.04.2023 & 18.07.2023	It was agreed his declaration would not prevent Professor Meads from participating in discussion on this appraisal.
Dr Matt Bradley	Committee member	Financial	Dr Bradley is an employee of GSK, a listed competitor company for this appraisal.	15.12.2022 & 11.04.2023	As a direct conflict of interest Dr Bradley did not participate in discussions on this appraisal.
Dr Nathan Moore	Committee member	Personal	Dr Moore provided talks to another department within employing organisation, which was arranged by them, on unrelated topic. However, the other department arranged, without his prior knowledge, for Pfizer to provide lunch and a 5-minute talk on Paxlovid and Rimegepant before providing my talk.	16.12.2022 & 03.04.2023 & 18.07.2023	As a direct conflict of interest Dr Moore did not participate in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Deborah Sloan	Patient expert	Financial	Deborah Sloan has received fees from Pfizer for being on a patient panel - giving insight into patient experience of migraine she confirmed she was not advising on any drug in particular but sharing personal experience on migraine as a whole. She also received fees for a presentation for Lundbeck - along the same lines - on her personal migraine experience.	11.10.2021 & 10.08.2023	It was agreed that her declarations would not prevent Deborah from providing expert advice to the committee.
Dr Brendan Davies	Clinical expert	Professional	Dr Davies is a member of the ABN Headache & Pain advisory group and has contributed to prior headache treatment consultations with NICE and attended as a nominated ABN clinical expert as part of the TA 361 assessment of Fremanezumab by NICE.	10.10.2021	It was agreed that his declarations would not prevent Dr Davies from providing expert advice to the committee.
Dr David Kernick	Clinical expert	Professional	Dr Kernick has advised AbbVie and Pfizer in this area.	10.08.2023	It was agreed that his declarations would not prevent Dr Kernick from providing expert advice to the committee.